Real-World Data Impact on Rare Disease Drug Label Expansion
Real-World Data Impact on Rare Disease Drug Label Expansion How Real-World Data Is Driving Drug Label Expansion in Rare Diseases Introduction: Why Real-World Data Matters in Rare Diseases Rare disease clinical development is often limited by small patient populations, short trial durations, and narrowly defined eligibility criteria. This can result in regulatory approvals that are…
Read More “Real-World Data Impact on Rare Disease Drug Label Expansion” »